tiprankstipranks
Tryptamine Therapeutics Limited (AU:TYP)
ASX:TYP
Australian Market
Holding AU:TYP?
Track your performance easily

Tryptamine Therapeutics (TYP) Income Statement

9 Followers

Tryptamine Therapeutics Income Statement

Last quarter (Q4 2022), Tryptamine Therapeutics's total revenue was AU$―, a decrease of ― from previous quarter. In Q4, Tryptamine Therapeutics's net income was AU$―. See Tryptamine Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 22Jun 21Jun 20Jun 19
Total Revenue
-AU$ 99.73K-AU$ 2.62M-
Cost of Revenue
-----
Gross Profit
-AU$ 99.73K-AU$ 2.62M-
Operating Expense
-AU$ 14.21MAU$ 12.67MAU$ 8.00MAU$ 2.31M
Operating Income
-AU$ -14.11MAU$ -12.67MAU$ -8.00MAU$ -2.31M
Net Non Operating Interest Income Expense
-AU$ -78.21KAU$ 7.05KAU$ 60.58KAU$ 28.79K
Other Income Expense
-AU$ 4.11MAU$ 4.19MAU$ 2.67M-
Pretax Income
-AU$ -10.08MAU$ -8.47MAU$ -5.28MAU$ -2.28M
Tax Provision
-AU$ 0.00AU$ 0.00AU$ 0.00AU$ 0.00
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
-AU$ -10.08MAU$ -8.47MAU$ -5.28MAU$ -2.28M
Basic EPS
-AU$ -0.06AU$ -0.06AU$ -0.06-
Diluted EPS
-AU$ -0.06AU$ -0.06AU$ -0.06-
Basic Average Shares
-AU$ 177.70MAU$ 130.60MAU$ 94.01M-
Diluted Average Shares
-AU$ 177.70MAU$ 130.60MAU$ 94.01M-
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
-----
Net Income From Continuing And Discontinued Operation
-AU$ -10.08MAU$ -8.47MAU$ -5.28MAU$ -2.28M
Normalized Income
-AU$ -10.08MAU$ -8.47MAU$ -5.28MAU$ -2.28M
Interest Expense
-AU$ 81.22K---
EBIT
-AU$ -10.00MAU$ -12.67MAU$ -8.00MAU$ -2.31M
EBITDA
-AU$ -8.27MAU$ -11.66MAU$ -7.62MAU$ -2.31M
Currency in AUD

Tryptamine Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis